Skip to main content
. 2021 Feb 8;6(7):4907–4920. doi: 10.1021/acsomega.0c05870

Figure 2.

Figure 2

Rational design of 4-oxoquinazoline-based N-hydroxypropenamides as HDAC inhibitors.